A lymphoma (non-Hodgkin or Hodgkin) arising from the central nervous system and occurring in HIV-positive patients.
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation surrounding AIDS-related primary CNS lymphoma is limited primarily due to its association with HIV, which affects a relatively specific population. Additionally, the rarity of the condition, coupled with the complexities of studying lymphomas in immunocompromised patients, has hindered systematic clinical research and characterization.
To navigate your care effectively, consider consulting with an oncologist who specializes in lymphoma, particularly one experienced with CNS lymphomas in HIV-positive patients. Resources such as the National Cancer Institute (cancer.gov) may provide additional insights and support. While there are currently no patient organizations identified for this specific condition, staying connected with general cancer support networks can be beneficial. Participation in any future registries or studies may also be an option as research evolves.
There are several orphan drugs designated for the treatment of AIDS-related primary CNS lymphoma, including (2S,5S)-5-(4-amino-5-(4-(2,3-difluorophenoxy)phenyl)imidazo[5,1-f][1,2,4]triazin-7-yl)tetrahydro-2H-pyran-2-yl)methanol and tirabrutinib. While no clinical trials are currently available, ongoing research may yield new treatment options. For updates on clinical trials, you can search ClinicalTrials.gov for related studies.
Actionable guidance for navigating care for AIDS-related primary central nervous system lymphoma
To navigate your care effectively, consider consulting with an oncologist who specializes in lymphoma, particularly one experienced with CNS lymphomas in HIV-positive patients. Resources such as the National Cancer Institute (cancer.gov) may provide additional insights and support. While there are currently no patient organizations identified for this specific condition, staying connected with general cancer support networks can be beneficial. Participation in any future registries or studies may also be an option as research evolves.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding AIDS-related primary CNS lymphoma is limited primarily due to its association with HIV, which affects a relatively specific population. Additionally, the rarity of the condition, coupled with the complexities of studying lymphomas in immunocompromised patients, has hindered systematic clinical research and characterization.
To navigate your care effectively, consider consulting with an oncologist who specializes in lymphoma, particularly one experienced with CNS lymphomas in HIV-positive patients. Resources such as the National Cancer Institute (cancer.gov) may provide additional insights and support. While there are currently no patient organizations identified for this specific condition, staying connected with general cancer support networks can be beneficial. Participation in any future registries or studies may also be an option as research evolves.
There are several orphan drugs designated for the treatment of AIDS-related primary CNS lymphoma, including (2S,5S)-5-(4-amino-5-(4-(2,3-difluorophenoxy)phenyl)imidazo[5,1-f][1,2,4]triazin-7-yl)tetrahydro-2H-pyran-2-yl)methanol and tirabrutinib. While no clinical trials are currently available, ongoing research may yield new treatment options. For updates on clinical trials, you can search ClinicalTrials.gov for related studies.
Actionable guidance for navigating care for AIDS-related primary central nervous system lymphoma
To navigate your care effectively, consider consulting with an oncologist who specializes in lymphoma, particularly one experienced with CNS lymphomas in HIV-positive patients. Resources such as the National Cancer Institute (cancer.gov) may provide additional insights and support. While there are currently no patient organizations identified for this specific condition, staying connected with general cancer support networks can be beneficial. Participation in any future registries or studies may also be an option as research evolves.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding AIDS-related primary CNS lymphoma is limited primarily due to its association with HIV, which affects a relatively specific population. Additionally, the rarity of the condition, coupled with the complexities of studying lymphomas in immunocompromised patients, has hindered systematic clinical research and characterization.
To navigate your care effectively, consider consulting with an oncologist who specializes in lymphoma, particularly one experienced with CNS lymphomas in HIV-positive patients. Resources such as the National Cancer Institute (cancer.gov) may provide additional insights and support. While there are currently no patient organizations identified for this specific condition, staying connected with general cancer support networks can be beneficial. Participation in any future registries or studies may also be an option as research evolves.
There are several orphan drugs designated for the treatment of AIDS-related primary CNS lymphoma, including (2S,5S)-5-(4-amino-5-(4-(2,3-difluorophenoxy)phenyl)imidazo[5,1-f][1,2,4]triazin-7-yl)tetrahydro-2H-pyran-2-yl)methanol and tirabrutinib. While no clinical trials are currently available, ongoing research may yield new treatment options. For updates on clinical trials, you can search ClinicalTrials.gov for related studies.
Actionable guidance for navigating care for AIDS-related primary central nervous system lymphoma
To navigate your care effectively, consider consulting with an oncologist who specializes in lymphoma, particularly one experienced with CNS lymphomas in HIV-positive patients. Resources such as the National Cancer Institute (cancer.gov) may provide additional insights and support. While there are currently no patient organizations identified for this specific condition, staying connected with general cancer support networks can be beneficial. Participation in any future registries or studies may also be an option as research evolves.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.